LY-320135

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H17NO4
Molecular Weight	383.3961
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(C=C1)C2=C(C(=O)C3=CC=C(C=C3)C#N)C4=CC=C(OC)C=C4O2

InChI

InChIKey=RYNSGDFWBJWWSZ-UHFFFAOYSA-N

InChI=1S/C24H17NO4/c1-27-18-9-7-17(8-10-18)24-22(20-12-11-19(28-2)13-21(20)29-24)23(26)16-5-3-15(14-25)4-6-16/h3-13H,1-2H3

HIDE SMILES / InChI

Molecular Formula	C24H17NO4
Molecular Weight	383.3961
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15670612 | https://www.ncbi.nlm.nih.gov/pubmed/9435190

LY-320135 is a substituted benzofuran which is structurally distinct from the aminoalkylindole and pyrazole type cannabinoid antagonists, AM630 and SR141716A, respectively. LY-320135 is a potent and selective canniboid CB1 receptor antagonist/inverse agonist. LY-320135 is selective (~70 fold) over canniboid CB2 receptors. LY-320135 is widely used in research, particularly for elucidating the mechanisms by which many CB1 antagonists act as inverse agonists at higher doses. LY-320135 shows weak binding to both 5-HT2 (Ki = 6.4 uM) and muscarinic receptors (Ki = 2.1 uM).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cannabinoid CB1 receptor 85 Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435190	Antagonist 2778		141.0 nM [Ki]
Serotonin 2 (5-HT2) receptor 87 Target ID: CHEMBL2095200 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9435190	Binding Agent 1064		6.4 µM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cerebral infarction 14 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15541895 https://www.ncbi.nlm.nih.gov/pubmed/21130785	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.	1998 Jan	9435190
Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization.	2009 Oct	19643997

Patents

Sample Use Guides

In Vivo Use Guide

Rats: pretreatment of rats with 6 mg/kg, i.v., LY-320135 resulted in reduction in infarct volume compared with vehicle treated rats.

Route of Administration: Intravenous

In Vitro Use Guide

LY-320135 blocked the anandamide + forskolin-mediated stimulation of cAMP accumulation with IC50 value of 734 nM in pertussis toxin-treated CHO-CB1 cells..

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:30:55 GMT 2023` Edited by `admin` on `Sat Dec 16 08:30:55 GMT 2023`
Record UNII	CJY03984CT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LY-320135

Common Name

English

(6-METHOXY-2-(4-METHOXYPHENYL)BENZO(B)FURAN-3-YL)(4-CYANOPHENYL)METHANONE

Systematic Name

English

BENZONITRILE, 4-((6-METHOXY-2-(4-METHOXYPHENYL)-3-BENZOFURANYL)CARBONYL)-

Systematic Name

English

Code System Code Type Description

CAS

176977-56-3